Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

The present invention provides, among other things, methods of treating pruritic or inflammatory skin diseases or disorders, or pruritus associated with a disease or disorder, with an anti-OSMR antibody, including methods of treating pruritus, associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, cutaneous amyloidosis, lichen simplex chronicus, plaque psoriasis, lichens planus, inflammatory ichthyosis, mastocytosis and bullous pemphigoid, comprising a step of administering to a subject in need of treatment an anti-OSMR antibody at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of the disease or disorder relative to a control.

The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.

The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers.

An in vitro co-culture system comprising cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for identifying agents capable of reducing cancer cell stemness. Also disclosed herein are a paracrine network through which CAFs facilitate production and/or maintenance of cancer stem cells and the use of components of such a paracrine network for prognosis purposes and for identifying cancer patients who are likely to respond to certain treatment.

The present invention relates to a kit for detecting a subset of a human regulatory T cell, and a detection method thereof, and belongs to the technical field of cell subset detection. The present invention provides a kit which includes the following components: a blood dilution solution, a mononuclear cell isolation solution, a cell culture solution, a lymphocyte activation liquid, a dead-cell-removing dye, an FcR blocking agent, fluorescence-labeled antibodies against human cell-surface markers, fluorescence-labeled antibodies against human intracellular molecules, a PBS buffer, lipopolysaccharide, a washing buffer, a cell staining buffer, a cell fixing solution, and a membrane-permeable wash buffer. At the time of detection, firstly mononuclear cells are isolated from whole blood, secondly human peripheral blood mononuclear cells are stimulated, and finally the subsets of the regulatory T cells can be detected just by fluorescent antibody staining. Use of the kit and detection method of the present invention can identify 2-6 subsets of regulatory T cells quickly and easily.

The present invention relates to a method for assessing whether a critically ill subject is in need of a renal replacement therapy, wherein the method comprises determining in a sample obtained from said subject the level of proadrenomedullin (proADM) or a fragment thereof, preferably the fragment is MR-proADM, wherein said level of proADM or the fragment thereof is indicative of a need of said subject to receive a renal replacement therapy.

The invention relates to a method for predicting the clinical response to a therapy based on the administration of mesenchymal stem cells (MSCs) in a patient suffering from an immune-mediated inflammatory disease. The invention also relates to methods of personalised medicine as well as to therapeutic uses of MSCs in a patient suffering from an immune-mediated inflammatory disease.

Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

The invention relates to a process for the in vitro diagnosis or prognosis of pre-eclampsia, comprising determining an increase or decrease in the concentration of one or more markers in a sample of biological fluid.